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CORRELATES OF COMPLETION RATE AND  
 
QUESTION COMPREHENSION FOR A MULTI-ETHNICITY ONLINE STUDY 
  
OF OVULATION AND MENSTRUATION HEALTH 
 
ANNA S. WILLIAMS 
ABSTRACT 
Background 
Polycystic ovary syndrome (PCOS), a diagnosis of exclusion, is considered the 
most common endocrinopathy in females of reproductive age. Current cohorts of 
individuals with PCOS exist but are limited, specifically in racial/ethnic diversity, due to 
the complexity of multiple choice survey questions and difficulty to obtain data.  
 
Methods 
After examining existing cohorts and their questionnaires, an online survey was 
designed specifically to assess PCOS characteristics in a diverse population. The survey 
was field tested for cognitive understanding and usability in a diverse population, with 
respect to race/ethnicity and education. After cognitive testing, the survey was launched 
online and participants were recruited to complete the survey.  
Survey completion rates by level of education, race/ethnicity, and birthplace were 
established by determining the proportion of participants in each subgroup to complete 
the entire survey. We also looked at the average percentage of the survey participants in 
each subgroup completed before discontinuing the survey. Univariate regression analyses 
were performed to evaluate these results. 
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Question comprehension was determined by evaluating all survey questions by 
length and complexity. The survey question asking participants to report their typical 
menstrual cycle length (MCL) was selected to assess participants’ question 
comprehension. Responses that fell outside of the normal range for MCL were examined 
and those that may have been inaccurate were isolated. Level of education and birthplace 
reported by participants who may have responded to the MCL question inaccurately were 
noted and assessed collectively. 
 
Results  
Two-hundred and forty-eight participants, aged 18-53 years, began the survey 
between August 9, 2017 and October 23, 2017. Of these participants, 71.7% identified as 
White; 11.7% as Hispanic, Latina, or of Spanish Origin; 12.6% as Black or African 
American; 13.2% as other races/ethnicities; and 9.2% as more than one race/ethnicity.  
Of the participants with some high school education, a high school diploma, or a 
GED, 74% completed the entire survey; of those with some college education or a 2-year 
degree, 81% completed the entire survey; and of those with a 4-year college degree or 
more, 90% completed the entire survey. On average, participants with a high school 
education completed 86% of the survey before discontinuing; those with some college 
education completed 91% of the survey before discontinuing; and those with a college 
degree or more completed 95% of the survey before discontinuing.  
Of the participants who identified as White, 92% completed the entire survey; of 
those who identified as Hispanic, Latina, or of Spanish Origin, 68% completed the entire 
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survey; and of those who identified as Black or African American, 70% completed the 
entire survey, with statistical significance (p = 0.002). On average, participants who 
identified as White completed 96% of the survey before discontinuing; those who 
identified as Hispanic, Latina, or of Spanish Origin completed 82% of the survey before 
discontinuing; and those who identified as Black or African American completed 86% of 
the survey before discontinuing, with statistical significance (p = 0.002). 
Of the participants who were born in the United States, 92% completed the entire 
survey, and of the participants who were not born in the United States, 66% completed 
the entire survey, with statistical significance (p < 0.0001). On average, participants who 
were born in the United States completed 96% of the survey before discontinuing and 
participants who were not born in the United States completed 81% of the survey before 
discontinuing, with statistical significance (p < 0.0001). 
When asked to report their typical MCL, 66 participants (28.1%) responded with 
irregular answers and 20 (8.5%) may have responded inaccurately. Of these 20 
participants, 18 (90%) completed at least some amount of college and 16 (80%) were 
born in the United States.  
 
Discussion  
This pilot study succeeds in establishing a cohort that is more racially/ethnically 
diverse than existing cohorts of individuals with PCOS. In order to gather more 
information on the ways in which PCOS manifests across different groups, future 
recruitment efforts ought to be more targeted towards individuals belonging to different 
		 viii 
racial/ethnic groups and socioeconomic statuses. Additionally, the baseline survey and 
future modules can be made more accessible to diverse groups through language 
translation. Furthermore, the addition of a menstrual cycle tracker component to the 
survey may increase the accuracy of information on participants’ menstrual cycle 
patterns. 
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INTRODUCTION 
 
Polycystic Ovary Syndrome 
Criteria. Polycystic ovary syndrome (PCOS), a diagnosis of exclusion, is 
considered the most common endocrinopathy in females of reproductive age; however, a 
consensus on diagnostic criteria for the syndrome has yet to be established (Azziz 2004; 
Chang 2004; Franks 1995; Kauffman 2008; Toulis 2009; Wood 2007). According to the 
National Institutes of Health (NIH), PCOS should be diagnosed in the presence of 
chronic oligo- or anovulation and clinical or biochemical hyperandrogenism, with the 
exclusion of related disorders (Zawadzki 1992). In 2004, the Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group revised the NIH definition of PCOS, 
concluding that the syndrome should be diagnosed in the case that at least two of the 
following three symptoms are present in the individual: 1.) chronic oligo- or anovulation, 
2.) clinical or biochemical hyperandrogenism, and 3.) polycystic ovaries on ultrasound 
(Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group). The 
Androgen Excess Society (AES) subsequently declared that clinical or biochemical 
hyperandrogenism is an essential component of the syndrome, concluding that PCOS 
should only be diagnosed in the presence of both hyperandrogenism (clinical or 
biochemical) and ovarian dysfunction (chronic oligo- or anovulation and/or polycystic 
ovaries) (Azziz 2006; Azziz 2009). 
Prevalence. A number of studies have aimed to ascertain the prevalence of PCOS. 
In a study on 728 females aged 27-34 years born in Adelaide, South Australia, who were 
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predominantly Caucasian (94% had European ancestry), PCOS prevalence was 8.7 ± 
2.0% according to the NIH criteria, 11.9 ± 2.4% according to the Rotterdam criteria (17.8 
± 2.8% when imputed), and 10.2 ± 2.2% according to the AES criteria (12.0 ± 2.4% 
when imputed) (March 2010). In a study on 1126 females aged 18-45 years from various 
regions of Iran, PCOS prevalence was 7.1% according to the NIH criteria, 14.6% 
according to the Rotterdam criteria, and 11.7% according to the AES criteria (Tehrani 
2011). In a study on 15,924 females aged 19-45 years from various regions of China, 
PCOS prevalence was 5.6% according to the Rotterdam criteria (Li 2013). In a study on 
863 females aged 20-40 years, who were employees of Copenhagen University Hospital, 
Rigshospitalet, in Copenhagen, Denmark, PCOS prevalence was 16.6% according to the 
Rotterdam criteria (Lauritsen 2014). In a systematic review and meta-analysis of 24 
studies reporting PCOS prevalence, overall PCOS prevalence was 6% (5-8%) according 
to the NIH criteria, 10% (8-13%) according to the Rotterdam criteria, and 10% (7-13%) 
according to the AES criteria (Bozdag 2016) (Table 1). 
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Table 1. Summary of PCOS Prevalence of Different Populations by Diagnostic 
Criteria. Data for Australia from March 2010; for Iran from Tehrani 2011; for China 
from Li 2013; for Denmark from Lauristen 2014; for Review from Bozdag 2016. 
 
 PCOS Prevalence by Criteria 
Study NIH Criteria Rotterdam Criteria AES Criteria 
Australia  8.7 ± 2.0% 11.9 ± 2.4% 17.8 ± 2.8%* 
10.2 ± 2.2% 
12.0 ± 2.4%* 
Iran  7.1% 14.6% 11.7% 
China  - 5.6% - 
Denmark  - 16.6% - 
Review 6% (5-8%) 10% (8-13%) 10% (7-13%) 
*Imputed result for the presence of polycystic ovaries in participants who did not consent 
to ultrasound  
 
 
 
PCOS prevalence estimates range from as low as 2.2% to as high as 26% due to 
the application of different diagnostic criteria on a variety of populations (Asuncion 
2000; Azziz 2004; Barth 2007; Chen 2008; Diamanti-Kandarakis 1999; Farah 1999; 
Franks 1995; Goodarzi 2005; Knochenhauer 1998; Kumarapeli 2008; March 2010; 
Michelmore 1999; Teimuraz 2005; Wang 2011). This wide range illustrates both the 
difference in PCOS prevalence across races/ethnicities and the result of implementing the 
different criteria (for instance, PCOS prevalence can double when implementing the 
Rotterdam criteria over the NIH or AES criteria) (Broekmans 2006; Lowe 2005). Figure 
1 portrays this. 
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Figure 1.  Global Prevalence of PCOS. Data for Australia from Boyle 2012, March 
2010; for Brazil from Gabrielli 2012; for China from Chen 2008, Li 2013, Ma 2010; for 
Denmark from Lauritsen 2014; for Greece from Diamanti-Kandarakis 1999; for India 
from Gill 2012; for Iran from Mehrabian 2011, Rashidi 2014, Tehrani 2011; for Italy 
from Sanchón 2012; for Mexico from Moran 2010; for Palestine from Musmar 2013; for 
Spain from Asunción 2000; for Sri Lanka from Kumarapeli 2008; for Thailand from 
Vutyavanich 2007; for United Kingdom from Michelmore 1999; for United States from 
Azziz 2004, Goodarzi 2005. 
 
 
 
Pathophysiology. There are multiple etiologies of PCOS. In one case, the 
hypothalamus releases increased levels of gonadotropin-releasing hormone (GnRH). 
When GnRH is hypersecreted, it selectively stimulates the release of luteinizing hormone 
(LH) over follicle-stimulating hormone (FSH) by the anterior pituitary. Higher levels of 
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LH than FSH (35 ± 4.6 mIU/mL and 10.3 ± 0.7 mIU/mL, respectively) result in greater 
stimulation of the theca cells (by LH) than the granulosa cells (by FSH) in the ovaries 
(DeVane 1975). Increased stimulation of the theca cells results in increased androgen 
production. Meanwhile, comparably decreased stimulation of the granulosa cells results 
in granulosa cell atresia and consequently decreased aromatase production (Diamanti-
Kandarakis 2012).  
Decreased aromatase levels prevent the conversion of androgen to estrogen, 
causing androgen levels to remain elevated (with testosterone, T, levels at 468 ± 41 
pg/mL vs. normal T levels at 325 ± 34 pg/mL, and androstenedione levels at 2083 ± 138 
pg/mL vs. normal androstenedione levels at 1123 ± 153 pg/mL) (DeVane 1975). 
Furthermore, obesity and hyperinsulinemia (components of metabolic syndrome, which 
is frequently seen in individuals with PCOS) decrease the availability of sex hormone-
binding globulin (SHBG), thus decreasing inhibition of androgen activity. It is also 
theorized that high levels of dehydroepiandrosterone (DHEA) are released by the adrenal 
cortex in individuals with PCOS due to hyper-responsiveness of the adrenal cortex to 
adrenocorticotropic hormone (ACTH), which is produced by the anterior pituitary upon 
stimulation by corticotropin-releasing hormone (CRH) from the hypothalamus. Increased 
DHEA (11.3 ± 1.7 mµg/mL vs. normal levels at 7.5 ± 1.2 mµg/mL) perpetuates elevated 
levels of androgen (DeVane 1975; Lachelin 1979; Yildiz 2007). Decreased estrogen 
(with estradiol, E2, levels at 58 ± 4 pg/mL vs. normal E2 levels at 63 ± 8 pg/mL) results 
in decreased follicular growth or follicular arrest. A low ratio of estrogen to androgen 
results in decreased sensitivity of the hypothalamus to estrogen and progesterone. This 
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decreased sensitivity prevents negative feedback by estrogen and progesterone on the 
hypothalamus to decrease GnRH release. Resultantly, hypersecretion of GnRH by the 
hypothalamus continues (Diamanti-Kandarakis 2012) (Table 2). 
 
Table 2. Hormone Levels in Non-PCOS and PCOS Females on Days 2-4 of the 
Menstrual Cycle. Data from DeVane 1975. 
 
Hormone Non-PCOS PCOS 
Luteinizing Hormone (LH)* 12.7 ± 2.6 mIU/mL 35 ± 4.6 mIU/mL 
Follicle-Stimulating Hormone (FSH) 8.7 ± 0.9 mIU/mL 10.3 ± 0.7 mIU/mL 
Estrone (E1)* 52  ± 5 pg/mL 92 ± 4 pg/mL 
Estradiol (E2) 63 ± 8 pg/mL 58 ± 4 pg/mL 
Testosterone (T)* 325 ± 34 pg/mL 468 ± 41 pg/mL 
Androstenedione* 1123 ± 153 pg/mL 2083 ± 138 pg/mL 
Dehydroepiandrosterone Sulfate (DHEAS)* 2.0 ± 0.37 mµg/mL 3.4 ± 0.4 mµg/mL 
Dehydroepiandrosterone (DHEA) 7.5 ± 1.2 mµg/mL 11.3 ± 1.7 mµg/mL 
*Statistically significant differences  
 
 
Hyperandrogenism may manifest in the form of hirsutism, increased acne, and/or 
alopecia (Diamanti-Kandarakis 2012; Goodarzi 2011). Follicular arrest results in 
infrequent ovulation and/or the formation of ovarian cysts (eventually, polycystic 
ovaries) (Hull 1987; Jonard 2003; Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group). 
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Health implications. The reproductive health implications of PCOS include 
infertility and endometrial cancer (Balen 1995; Dahlgren 1991; Mulders 2004; 
Navaratnarajah 2008; Tehrani 2010). Metabolic risk factors include obesity, insulin 
resistance, type 2 diabetes mellitus (T2DM), metabolic syndrome, dyslipidemia, 
cardiovascular diseases (CVD), and sleep apnea (Amowitz 1999; Christakou 2008; Chun-
Sen 2010; Dokras 2008; Ehrmann 2006; El-Mazny 2010; Essah 2007; Shaw 2008; Stepto 
2013; Talbott 2004; Teede 2010). Psychological implications include depression, anxiety, 
and low self-esteem (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop 
Group; Teede 2007; Meyer 2005). 
Existing cohorts. The Cape Cod Health Study (CCHS), the Framingham Heart 
Study and Omni Cohorts (FHS/OMNI), and the Nurses’ Health Study 2 (NHS2) are large 
population-based cohorts that were established without aiming to ascertain PCOS 
prevalence but report PCOS-related findings. Limitations of these include lack of 
thorough PCOS phenotyping, too few reported cases of menstrual irregularity, and poor 
correlation between PCOS self-reporting and PCOS in medical records (Chavarro 2016; 
Mahalingaiah 2016; Mahalingaiah 2017). Furthermore, these cohorts lack racial/ethnic 
diversity, with over 90% of participants being Caucasian. As a result of these limitations, 
the various phenotypes of PCOS, and the ways in which these phenotypes present 
themselves across varying races/ethnicities, the global burden of PCOS cannot be 
assessed accurately. A cohort designed specifically to evaluate PCOS characteristics is 
needed. 
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Specific Aims 
 
We designed an online survey, the Ovulation and Menstruation Health Study (OM 
Health Study) to establish a multi-ethnicity cohort of individuals with PCOS and a 
comparison cohort of healthy females. In order to determine correlates for survey 
completion rate and question comprehension of the baseline questionnaire, this thesis 
aims to: 
1. Evaluate the relationship between survey completion rate and 
a. Level of education 
b. Race/ethnicity 
c. Birthplace 
2. Determine participants’ ability to comprehend menstrual cycle length and respond 
to questions regarding menstrual cycle length by 
a. Level of education 
b. Birthplace 
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METHODS 
 
Survey Design 
In an effort to establish a multi-ethnicity cohort of individuals with PCOS, the 
Mahalingaiah Lab at Boston University School of Medicine (BUSM) designed an online 
survey, the OM Health Study. The survey was written after examining existing cohorts 
and their questionnaires, including the CCHS, the Growing Up Today Study (GUTS), the 
FHS, the LIFE Health Care Study, the NHS2, the Pregnancy Study Online (PRESTO), 
and Project Viva. The OM Health Study survey was developed by a board-certified 
reproductive endocrinology/infertility physician-scientist and includes questions 
concerning demographics, anthropometrics, menstrual cycle health, contraceptive use, 
medication and supplement use, PCOS status, reproductive health, general health, diet 
and lifestyle, and pregnancy and birth history. A licensed medical illustrator created 
images for questions on body shape and hair growth. The survey was written at an 8th-
grade reading level and tested for cognitive understanding and usability for a diverse 
population, with respect to race/ethnicity and education. 
 
Eligibility 
Individuals were deemed eligible to participate in the study if they were 18 years 
of age or older and identified as female, trans male, or “other” gender. Individuals were 
deemed ineligible to participate if they were under 18 years of age, identified as male, 
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were pregnant at the time of participation, had a hysterectomy, or had been exposed to 
radiation or chemotherapy. 
 
Recruitment 
After cognitive testing, the survey was launched online and made available to the 
public. The survey could be accessed through the study website, which also exhibited a 
two-minute animated video on ovulation and menstruation to introduce the study. Flyers 
for the study with the hyperlink and a Quick Response Code (QR code) to the study 
website were posted around the Boston Medical Center (BMC) campus, the BUSM 
campus, the Boston University School of Public Health (BUSPH) building, and the 
Boston University Charles River Campus (BUCRC). Recruitment letters were sent to 
patients with OB/GYN and endocrinology appointments at BMC during scheduled 
recruitment hours. The recruitment letters introduced recipients to the OM Health Study 
and explained that study staff might be recruiting participants for the study in the clinic 
waiting room during their visit. The letters provided recipients with a hyperlink to the 
study website and an email address to contact the research team. 
The study staff recruited participants in-person in OB/GYN and endocrinology 
waiting rooms at BMC and at the Boston Women’s Market, a community fair, in the 
Jamaica Plain neighborhood of Boston, MA. In-person recruitment was achieved by 
having participants complete a consent form and screener on an electronic tablet. If 
participants were eligible to complete the survey, the form asked the participant to 
provide an email address. A link to the survey was then sent to the participant’s email. 
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Participants recruited at BMC were given the option to begin the survey in the waiting 
room while waiting for their appointment. A return code was provided to participants 
who started but did not complete the survey. Participants recruited at the Boston 
Women’s Market were encouraged to complete the survey at home. 
The study staff also recruited participants for the study online using Facebook. A 
Facebook Page for the study was created and the study staff posted information on the 
study in various Facebook Groups. While recruiting, the study staff posted related articles 
on the Facebook Page to maintain interest and to remind Followers of the survey. 
Furthermore, information on the study appeared in the weekly Boston University Medical 
Campus (BUMC) News and Events email with Institutional Review Board (IRB) 
approval by BUMC. 
 
Assessment of Completion Rate  
Survey completion rates by level of education, race/ethnicity, and birthplace were 
established by determining the proportion of participants in each subgroup to complete 
the entire survey. We also looked at the average percentage of the survey participants in 
each subgroup completed before discontinuing the survey. 
 
Assessment of Question Comprehension 
Question comprehension was determined by evaluating all survey questions by 
length and complexity. The survey question asking participants to report their typical 
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menstrual cycle length (MCL) was selected to assess participants’ question 
comprehension.  
Participants were provided with a definition of MCL (the number of days from 
the first day of one menstrual period to the first day of the next menstrual period) and a 
normal range for MCL (21 to 35 days) (Figure 2). They were subsequently asked to 
report their typical MCL. Participants who selected “don’t know” when asked to report 
MCL were asked to take a guess.  
 
Figure 2. Menstrual Cycle Diagram. Menstrual cycle length (MCL) is defined as the 
number of days from the first day of one menstrual period to the first day of the next 
menstrual period. The normal range for MCL is 21-35 days. 
 
 
 
Irregularities. We defined a “short” MCL as less than 21 days, a “normal” MCL 
as 21 to 35 days, and a “long” MCL as greater than 35 days. The following were 
considered “irregular” responses to the MCL question:  
1. Less than 21 days (short) 
2. 21 days 
3. More than 35 days (long) 
4. “Don’t know” 
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While an MCL of 21 days is “normal,” reporting 21 days was considered irregular 
because participants may have responded with 21 days, having misinterpreted the 
definition of MCL as the number of days from the last day of one menstrual period to the 
first day of the next menstrual period, rather than as the number of days from the first day 
of one menstrual period to the first day of the next menstrual period. 
Inaccuracies. The following were considered potentially “inaccurate” responses 
to the MCL question:  
1. Reporting an MCL of < 21 days, 21 days, or > 35 days without reporting any 
other menstrual irregularities 
2. Selecting “don’t know” and then selecting a normal range 
3. Selecting “don’t know” and then selecting an irregular range without reporting 
any other menstrual irregularities 
4. Selecting “don’t know” and then selecting “still not sure” without reporting any 
other menstrual irregularities 
Responses that may have been inaccurate (based on the participants’ responses to 
questions in the menstrual cycle health, contraceptive use, PCOS status, and reproductive 
health sections of the survey) were further evaluated (Appendix 1). Level of education 
and birthplace reported by participants who may have responded to the MCL question 
inaccurately were noted and assessed collectively. 
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Statistical Analysis 
Univariate analyses were performed to evaluate completion rate. Fisher’s Exact 
test was used to compare the proportion of participants to complete the entire survey in 
each subgroup for level of education and race/ethnicity. The Kruskal-Wallace test was 
used to compare the average percentage of the survey participants responded to before 
discontinuing the survey in each subgroup for level of education and race/ethnicity. The 
Chi-squared test was used to compare the proportion of participants to complete the 
entire survey between participants born in the United States and those born outside of the 
United States. The Wilcoxon Rank-Sum test was used to compare the average percentage 
of the survey participants responded to before discontinuing the survey between 
participants born in the United States and those born outside of the United States.	  
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RESULTS 	
Demographics 
 
 Between August 9, 2017 and October 23, 2017, 389 participants approached the 
survey consent form. Of those participants, 99.0% completed the consent form and 98.7% 
started the screener. Of the 384 participants who started the screener, 355 completed it 
and 316 screened in. Two-hundred and forty-eight (63.8% of those who approached the 
consent form) began the survey and 214 (55.0%) completed the entire survey (Table 3).   
 
Table 3. Summary of Survey Completion 
 
Survey Completion Participants 
Approached Consent Form 389 (100%) 
Completed Consent Form 385 (99.0%) 
Consented 384 (98.7%) 
Approached Screener 384 (98.7%) 
Completed Screener 355 (91.3%) 
Screened In 316 (81.2%) 
Approached Survey 248 (63.8%) 
Completed Survey 214 (55.0%) 
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The 248 participants who began the pilot survey after completing the consent 
form and screener were aged 18-53 years, 27.6 years on average. Nearly all participants 
identified as female (99.2%) and reported currently living in the United States (98.0%). 
Of those who reported currently living in the United States, 68.6% lived in the Northeast 
and 25.8% lived in the Midwest. One hundred and ninety-nine participants (80.9%) were 
born in the United States and 47 participants (19.1%) were not born in the United States. 
One hundred and seventy-seven participants (71.7%) identified as White; 29 participants 
(11.7%) identified as Hispanic, Latina, or of Spanish Origin; 31 participants (12.6%) 
identified as Black or African American; 33 participants (13.2%) identified as other 
races/ethnicities; and 23 participants (9.2%) as more than one race/ethnicity. Nineteen 
participants (7.8%) had only completed some amount of high school, graduated from 
high school, or passed the GED; 36 participants (14.8%) had only completed some 
amount of college or had completed a 2-year degree; and 189 participants (77.5%) had 
graduated from a 4-year college or more (Table 4). 
 
Table 4. Summary of Pilot Sample Demographics 
  
Age (years)  
Range 
Mean (standard deviation) 
Median (25th percentile, 75th percentile) 
18-53  
27.6 (6.6) 
25.0 (23, 31) 
Gender  
Female 
Trans male 
Other 
246 (99.2%) 
0 
2 (0.8%) 
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Residence by Country  
United States 
Other 
242 (98.0%) 
5 (2.0%) 
Residence by Region of the United States  
Northeasta 
Midwestb 
Southc 
Westd 
162 (68.6%) 
61 (25.8%) 
7 (3.0%) 
6 (2.5%) 
Birthplace  
United States 
Other 
199 (80.9%) 
47 (19.1%) 
Race/Ethnicitye  
White 
Hispanic, Latina, or Spanish Origin 
Black or African American  
East Asian 
Southeast Asian 
South Asian 
American Indian or Alaskan Native 
Middle Eastern or North African  
Native Hawaiian or Other Pacific Islander 
Some other race, ethnicity, or origin 
> 1 race/ethnicity 
177 (71.7%) 
29 (11.7%) 
31 (12.6%) 
7 (2.8%) 
8 (3.2%) 
5 (2.0%) 
5 (2.0%) 
3 (1.2%) 
1 (0.4%) 
4 (1.6%) 
23 (9.2%) 
Level of Education  
Some high school, high school graduate, or GED 
Some college or 2-year degree 
4-year college graduate or more 
19 (7.8%) 
36 (14.8%) 
189 (77.5%) 	 	
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Annual Household Incomef  
Below $15,000 
$15,000 – $24,999 
$25,000 – $49,999 
$50,000 – $74,999 
$75,000 – $99,999 
$100,000 – $124,999 
$125,000 – $149,999 
$150,000 – $199,999 
≥$200,000 
Prefer not to answer 
Don’t know 
25 (10.2%) 
28 (11.5%)  
62 (25.4%) 
41 (16.8%) 
16 (6.6%) 
12 (4.9%) 
4 (1.6%) 
7 (2.9%) 
14 (5.7%) 
16 (6.6%) 
19 (7.8%) 
aThe Northeast was defined as New England (CT, ME, MA, NH, RI, VT) and the Mid-
Atlantic (NJ, NY, PA) 
bThe Midwest was defined as the East North Central region (IL, IN, MI, OH, WI) and the 
West North Central region (IA, KS, MN, MO, NE, ND, SD) 
cThe South was defined as the South Atlantic region (DE, FL, GA, MD, NC, SC, VA, 
DC, WV), the East South Central region (AL, KY, MS, and TN), and the West South 
Central region (AR, LA, OK, TX) 
dThe West was defined as the Mountain region (AZ, CO, ID, MT, NV, NM, UT, WY) 
and the Pacific region (AK, CA, HI, OR, WA) 
eParticipants could report more than one race. As a result, the sum of the percent 
frequencies reported in this section of Table 4 exceeds 100%. 
fIndividual household income could not be calculated using annual household income and 
number of individuals per household because annual household income was reported as a 
range. 
 
 
 
Completion Rate 
 
Level of education. Of the participants with some high school education, a high 
school diploma, or a GED, 74% completed the entire survey; of those with some college 
education or a 2-year degree, 81% completed the survey; and of those with a 4-year 
college degree or more, 90% completed the survey (Table 5). This comparison did not 
reach statistical significance using Fisher’s Exact test. On average, participants with some 
high school education, a high school diploma, or a GED completed 86% of the survey 
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before discontinuing; those with some college education or a 2-year degree completed 
91% of the survey before discontinuing; and those with a 4-year college degree or more 
completed 95% of the survey before discontinuing (Table 5). This comparison did not 
reach statistical significance using the Kruskal-Wallace test. 
 
Table 5. Completion Rate by Level of Education  
  
Level of Education Participants Who Completed Entire Survey 
Average % of Survey 
Completed Before 
Discontinuing 
Some high school, high school 
graduate, or GED (n = 19) 14 (74%) 86% 
Some college or 2-year degree 
(n = 36) 29 (81%) 91% 
4-year college graduate or more 
(n = 189) 170 (90%) 95% 
 
 
 
Race/ethnicity. Of the participants who identified as White, 92% completed the 
entire survey; of those who identified as Hispanic, Latina, or of Spanish Origin, 68% 
completed the entire survey; of those who identified as Black or African American, 70% 
completed the survey; of those who identified as East Asian or Southeast Asian, 100% 
completed the survey; of those who identified as South Asian, 80% completed the survey; 
and of those who identified as more than one race, 91% completed the survey (Table 6). 
This comparison reached statistical significance using Fisher’s Exact test (p = 0.002). On 
average, participants who identified as White completed 96% of the survey before 
discontinuing; those who identified as Hispanic, Latina, or of Spanish Origin completed 
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82% of the survey before discontinuing; those who identified as Black or African 
American completed 86% of the survey before discontinuing; those who identified as 
East Asian or Southeast Asian completed 100% of the survey before discontinuing; those 
who identified as South Asian completed 91% of the survey before discontinuing; and 
those who identified as more than one race/ethnicity completed 98% of the survey before 
discontinuing (Table 6). This comparison reached statistical significance using the 
Kruskal-Wallace test (p = 0.002).		
Table 6. Completion Rate by Race/Ethnicity 
 
Race/Ethnicity Participants Who Completed Entire Survey 
Average % of Survey 
Completed Before 
Discontinuing 
White (n = 177) 163 (92%) 96% 
Hispanic, Latina, or Spanish 
Origin (n = 29) 20 (68%) 82% 
Black or African American  
(n = 31)  22 (70%) 86% 
East Asian (n = 7) 7 (100%) 100% 
Southeast Asian (n = 8) 8 (100%) 100% 
South Asian (n = 5) 4 (80%) 91% 
> 1 race/ethnicity (n = 23) 21 (91%) 98% 
 
 
 
Birthplace. Of the participants who were born in the United States, 92% 
completed the entire survey, and of the participants who were not born in the United 
States, 66% completed the entire survey (Table 7). This comparison reached statistical 
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significance using the Chi-squared test (p < 0.0001). On average, participants who were 
born in the United States completed 96% of the survey before discontinuing and 
participants who were not born in the United States completed 81% of the survey before 
discontinuing (Table 7). This comparison reached statistical significance using the 
Wilcoxon Rank-Sum test (p < 0.0001). 
 
Table 7. Completion Rate by Birthplace 
 
Birthplace Participants Who  Completed Entire Survey 
Average % of Survey 
Completed Before 
Discontinuing 
United States (n = 199) 183 (92%) 96% 
Other (n = 47) 31 (66%) 81% 
 
 
 
Question Comprehension  
Menstrual cycle length. Of the 248 participants who began the pilot survey, 235 
(94.8%) responded when asked to report their typical MCL. One participant (0.4%) 
reported a short MCL (less than 21 days), 180 participants (76.6%) reported a normal 
MCL (21 to 35 days), and 16 participants (6.8%) reported a long MCL (greater than 35 
days). Thirty-eight participants (16.2%) initially selected “don’t know” (Table 8). 
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Table 8. Short, Normal, and Long Menstrual Cycle Length Responses 
 
 Self-Reported MCL Participants 
Short < 21 days 1 (0.4%) 
Normal 
21-25 days 
26-29 days 
30-35 days 
29 (12.3%) 
93 (39.6%) 
58 (24.7%) 
Long > 35 days 16 (6.8%) 
 “Don’t Know” 38 (16.2%) 
 
 
 
Irregularities. Of the 235 participants who responded when asked to report their 
typical MCL, 66 (28.1%) responded with irregular answers (less than 21 days, 21 days, 
more than 35 days, or “don’t know”). One participant reported an MCL of less than 21 
days, 11 participants reported an MCL of 21 days, 16 participants reported an MCL of 
more than 35 days, and 38 participants initially selected “don’t know” (Table 9). 
 
Table 9. Irregular Responses to Menstrual Cycle Length Question 
 
Irregular Response Participants 
< 21 days (short) 1 (2%) 
21 days 11 (17%) 
> 35 days (long) 16 (24%) 
“Don’t know” 38 (58%) 
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Inaccuracies. Of the 66 participants who responded with irregular answers, 20 
participants may have responded with inaccurate answers (Table 10).  
 
Table 10. Potentially Inaccurate Responses to Menstrual Cycle Length Question 
ID Age  Birthplace  Educationa MCLb (days) Menstrual  Irregularityc 
242 27 United States College graduate 21 No 
385 23 Indonesia More than college  21 No 
22 22 United States College graduate DK → 30-31 No 
51 24 United States More than college DK → 21-25 Yes 
56 22 United States Some college DK → 26-29 Yes 
63 22 United States College graduate DK → 26-29 Yes 
77 24 United States College graduate DK → 26-29 Yes 
93 27 Costa Rica College graduate DK → 26-29 No 
98 19 United States High school graduate DK → 30-31 No 
105 25 United States More than college DK → 26-29 Yes 
114 23 United States More than college DK → 21-25 Yes 
121 22 United States More than college DK → 21-25 Yes 
145 22 United States College graduate DK → 26-29 No 
183 24 Canada No response DK → 26-29 Yes 
189 26 United States More than college DK → 26-29 Yes 
221 31 United States College graduate DK → 26-29 No 
249 23 United States College graduate DK → 21-25 No 
277 35 Haiti More than college DK → 30-31 Yes 
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351 33 United States Some college DK → 32-35 Yes 
343 26 United States College graduate DK → NS No 
a“High school graduate” denotes “high school graduate or GED,” “some college” denotes 
“some college or 2-year degree,” “college graduate” denotes “4-year college graduate,” 
and “more than college” denotes “more than 4-year college degree.” 
bDK denotes “don’t know” and NS denotes “I’m still not sure” 
cThe presence of menstrual irregularities were determined by participants’ responses to 
questions in the menstrual cycle health, contraceptive use, PCOS status, and reproductive 
health sections of the survey (Appendix 1). 
 
 
 
Of the 20 participants who may have responded with inaccurate answers when 
asked to report their typical MCL, 16 (80%) were born in the United States, while the 
remaining four were born in countries whose official language is not English (with the 
exception of Canada, whose official languages are both English and French). Eighteen 
(90%) of these participants have completed at least some amount of college (Table 11). 
 
Table 11. Birthplace and Level of Education of Participants Who Provided 
Potentially Inaccurate Responses to Menstrual Cycle Length Question 
 
Birthplace 
 
United States 
Other 
16 (80%) 
4 (20%) 
Level of Education  
Some high school, high school graduate, or GED 
Some college or 2-year degree 
4-year college graduate or more  
No response 
1 (5%) 
2 (10%) 
16 (80%) 
1 (5%) 	
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DISCUSSION 
 
The Pilot Sample 
This pilot study was successful in establishing a cohort that is more 
racially/ethnically diverse than existing cohorts of individuals with PCOS (Table 12). 
This success can be attributed to the study staff’s in-person recruitment efforts in 
OB/GYN clinic waiting rooms at BMC, due to the diverse profile of the patients who 
attend these clinics. Of the clinics that the study staff recruited from, the Doctor’s Office 
Building (DOB) was the most successful site because of the waiting room environment. 
The DOB OB/GYN clinic waiting room was relatively small—compared to that of the 
Yawkey Ambulatory Care Center, another site of in-person recruitment—and thus had 
fewer patients at any given time, creating a calmer environment that allowed the study 
staff to more readily approach patients (Figures 3 and 4). Furthermore, patients in the 
DOB OB/GYN clinic waiting room typically had longer wait times than patients in the 
Yawkey OB/GYN clinic waiting room, giving DOB patients the opportunity to complete 
the survey while in the clinic, rather than having to return to it later on. The study staff 
also recruited participants in-person in BMC’s Contraceptive Clinic, a smaller area within 
the Yawkey OB/GYN clinic. Recruitment in the Contraceptive Clinic was more 
successful than recruitment in the Yawkey OB/GYN clinic waiting room because patients 
attending the Contraceptive Clinic were more likely to be eligible to participate in the 
study. Patients attending the Contraceptive Clinic, however, had extremely short wait 
times, making it difficult to fully engage participants in the survey while in clinic.  
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Table 12. Racial/Ethnic Profiles of Existing Cohorts of Individuals with PCOS and 
the OM Health Study. Data for Australia from March 2010; for Iran from Tehrani 2011; 
for China from Li 2013; for Denmark from Lauristen 2014. 
 
Study Racial/Ethnic Profile 
Australia  94% White 
Iran  100% Middle Eastern  
China  100% East Asian 
Denmark  97.3% White 
OM Health Study 
71.7% White 
11.7% Hispanic, Latina, or Spanish Origin 
12.6% Black or African American 
2.8% East Asian 
3.2% Southeast Asian 
2.0% South Asian 
2.0% American Indian or Alaskan Native 
1.2% Middle Eastern or North African  
0.4% Native Hawaiian or Other Pacific Islander 
1.6% Some other race, ethnicity, or origin 
9.4% More than one race 
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Figure 3. Doctor’s Office Building OB/GYN Clinic Waiting Room. Photos of the 
DOB OB/GYN clinic entrance (top) and waiting room (bottom). Photos taken by Alicia 
Peterson, Operations Manager at BMC. 
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Figure 4. Yawkey Ambulatory Care Center OB/GYN Clinic Waiting Room. Photos 
of the Yawkey OB/GYN clinic entrance (top) and waiting room (bottom). Photos taken 
by Jill MacRae, Project Manager for Research, Recruitment, and Retention at Boston 
University Clinical and Translational Science Institute. 
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While the racial/ethnic diversity of the pilot sample can be attributed to in-person 
recruitment in OB/GYN clinic waiting rooms at BMC, the study staff was successful in 
creating a sizeable pilot sample due to in-person recruitment efforts at the Boston 
Women’s Market. Individuals who chose to attend the Market were interested in learning 
about ongoing research in Women’s Health and felt an obligation to contribute to medical 
research. As a result, a significant number of individuals who the study staff approached 
at the Market were eager to participate in the OM Health Study and felt compelled to 
complete the survey later on.  
While this pilot sample is more racially/ethnically diverse than existing cohorts of 
individuals with PCOS, it is a convenience sample, primarily due to the online 
recruitment efforts of the study staff. In an effort to establish a sizeable pilot cohort, the 
study staff recruited participants from personal networks, which yielded a sample 
composed primarily of individuals currently living in the United States (particularly in 
the Northeast and Midwest regions of the country), individuals who were born in the 
United States, individuals who identify as White, and individuals who have graduated 
from a 4-year college or completed higher education.  
In order to gather more information on the ways in which PCOS manifests across 
different groups, future recruitment efforts may be more targeted towards individuals 
with lower socioeconomic statuses. For instance, in-person recruitment should be 
continued at BMC—while focusing on clinics that provide an appropriate environment 
for recruitment—and expanded to neighboring healthcare facilities to reach low-income 
patients belonging to diverse racial/ethnic categories. Furthermore, recruitment efforts 
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should target racially-/ethnically-focused community events, similar to the Boston 
Women’s Market in Jamaica Plain, but with greater racial/ethnic diversity.  
 
Variable Selection 
Level of education, race/ethnicity, and birthplace were selected as variables to 
determine the accessibility of the pilot survey to diverse populations. Birthplace was 
selected as a variable as it indicates participants’ primary language and thus ability to 
read and comprehend the English language version of the survey. Because birthplace is 
not an entirely reliable indication of primary language, a question asking participants to 
indicate primary language ought to be added to the baseline survey. Income was not 
selected as a variable in this study due to the difficulty of assessing the income of 
younger participants who may be under the care or support of family. While participants 
were asked to report annual household income and the number of individuals per 
household, younger participants may have provided their parents’ household income 
while belonging to a different household. As a result, a question whose response can 
better summarize participant income and socioeconomic status ought to be added to the 
baseline survey. 
 
Completion Rate 
There may be an association between factors such as level of education and 
birthplace, and survey completion. Participants identifying as White, East Asian, 
Southeast Asian, and South Asian had greater rates of completion compared to those 
identifying as Hispanic, Latina, of Spanish Origin, Black, and African American, within 
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their own racial/ethnic category. Participants who were born in the United States had 
greater completion compared to those who were not born in the United States. These 
findings indicate the importance of translating the baseline survey and future modules 
into multiple languages.  
 
Question Comprehension 
Level of education and birthplace did not affect participants’ ability to 
comprehend MCL and respond to questions regarding MCL. A large number of 
participants, however, may have responded to the question inaccurately, even after being 
provided with a definition of MCL and a normal range for MCL. In order to gain accurate 
information on MCL, an alternate measure ought to be implemented, such as a menstrual 
cycle tracker app that participants can update daily as they progress through their 
menstrual cycle. Furthermore, a menstrual cycle tracker app would reveal any 
discrepancies between one cycle and the next, rather than simply requesting averages or 
“typical” menstrual cycle details.  
 
Conclusion 
This pilot study succeeds in establishing a cohort that is more racially/ethnically 
diverse than existing cohorts of individuals with PCOS. In order to gather more 
information on the ways in which PCOS manifests across different groups, future 
recruitment efforts ought to be more targeted towards individuals belonging to different 
racial/ethnic groups and socioeconomic statuses. Additionally, the baseline survey and 
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future modules can be made more accessible to diverse groups through language 
translation. Furthermore, the addition of a menstrual cycle tracker component to the 
survey may increase the accuracy of information on participants’ menstrual cycle 
patterns.
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APPENDIX 1: QUESTIONS USED TO DETERMINE POTENTIALLY 
INACCURATE RESPONSES TO MENSTRUAL CYCLE LENGTH QUESTION 
 
1. At what age did you have your first menstrual period? 
2. Sometimes when a woman first gets her period, it’s not on a regular schedule and 
she may go months between periods. Thinking back to when you first got your 
period, how long did it take for your menstrual periods to become regular? 
3. Did your period become regular on its own—that means without taking the Pill or 
using any other hormonal contraceptives (patch, implants, or injectables)? 
4. Has there ever been a time when your menstrual period was NOT regular or 
predicable for more than a 3 month window of time? 
5. Why do you think were your periods were irregular? 
a. Stress 
b. Polycystic ovary syndrome (PCOS) 
c. Hormonal abnormality 
d. Too much exercise and not eating enough 
e. Overweight/obesity 
f. Pregnancy/breastfeeding 
g. Other, please specify 
h. Don't know 
6. We are interested in whether your menstrual period is regular now—that means 
you can usually predict about when the next period will start. Would you say that 
your period is usually regular? 
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7. Now we want to know about how long your period usually lasts. Counting only 
the days when you were bleeding and not when you were spotting, in the last year 
about how many days did your period usually last? 
8. In the last 12 months, how many menstrual periods did you have? 
9. Hormonal contraceptives include the pill, patch, implants, or injectables. Have 
you ever used hormonal contraceptives? 
10. Do you currently use any hormonal contraceptives? 
11. Are you currently taking hormonal contraceptives to help regulate your menstrual 
periods so they are more regular and predictable?  
12. Polycystic Ovary Syndrome is a health condition involving irregular periods, 
excess testosterone, increased acne, body and facial hair, and many small cysts in 
the ovaries. Some women also experience hair loss on the scalp. Has a doctor ever 
diagnosed you? 
13. Do you think you might have PCOS? 
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